Table 1.
Overview and overview differences STS and LTS (15 vs. 36 months).
| Parameters | Overall (n = 75) [Median (Range)] |
STS (n = 49) [Median (Range)] |
LTS (n = 26) [Median (Range)] |
Significance (LTS vs. STS) |
|---|---|---|---|---|
| WHO grade (III/IV) | 20 (26.7%)/55 (73.3%) | 9 (18.4%)/40 (81.6%) | 11 (42.3%)/15 (57.7%) | p = 0.032 |
| MGMT (methyl./unmethyl.) | 38 (50.7%)/37 (49.3%) | 17 (34.7%)/32 (65.3%) | 21 (80.8%)/5 (19.2%) | p < 0.001 |
| TERTp (mutation/wildtype) * | 60 (81.1%)/14 (18.9%) * | 44 (89.8%)/4 (10.2%) | 16 (61.5%)/10 (38.5%) | p = 0.004 |
| KPS | 80 (40.0–100.0) | 80.0 (40.0–100.0) | 90.0 (70.0–100.0) | p = 0.056 |
| Age [yrs] | 61.9 (33.5–77.2) | 64.0 (40.5–77.2) | 55.8 (33.5–71.9) | p = 0.001 |
| Sex (m/f) | 45 (60.0%)/30 (40.0%) | 31 (63.3%)/18 (36.7%) | 14 (53.8%)/12 (46.2%) | p = 0.466 |
| CE (y/n) | 66 (88.0%)/9 (12.0%) | 47 (95.9%)/2 (4.1%) | 19 (73.1%)/7 (26.9%) | p = 0.070 |
| Diameter CE [cm] | 25.0 (0.0–72.0) | 27.0 (0.0–72.0) | 24.5 (0.0–62.0) | p = 0.406 |
| Volume CE [ml] | 5.7 (0.0–128.7) | 5.7 (0.0–128.7) | 5.8 (0.0–46.3) | p = 0.802 |
| Surgery/Biopsy | 26 (34.7%)/49 (65.3%) | 12 (24.5%)/37 (75.5%) | 14 (53.8%)/12 (46.2%) | p = 0.021 |
| 18F-FET-positive (y/n) | 74 (98.7%)/1 (1.3%) | 48 (98.0%)/1 (2.0%) | 26 (100.0%)/0 (0.0%) | p = 1.000 |
| TBRmean | 2.0 (0.8–2.9) | 2.0 (0.8–2.9) | 1.9 (1.7–2.6) | p = 0.227 |
| TBRmax | 3.11 (1.5–6.1) | 3.2 (1.5–6.1) | 2.9 (1.9–4.9) | p = 0.127 |
| BTV [ml] | 22.8 (0.0–133.26) | 27.4 (0.0–133.2) | 16.5 (1.8–89.5) | p = 0.017 |
| TTPmin [min] | 12.5 (7.5–35.0) mean/SD: 13.9 ± 6.4 |
12.5 (7.5–35.0) mean/SD: 9.9 ± 6.3 |
12.5 (7.5–35.0) mean/SD: 13.3 ± 5.1 |
p = 0.008 |
* TERT available in 74/75 patients, the 1 patient without TERT status is in the STS-group.